IonQ RPO Surge Adds Backlog Ammo But Wait Thesis Holds

What happened

IonQ's Q2 RPO reached $485 million, up 297% year-over-year and outpacing the 287% revenue growth, while organic revenue rose 132% YoY, above management's full-year target. The RPO growth occurred despite record revenue recognition, indicating new contracted business is arriving faster than existing backlog converts to sales. However, the RPO includes unfunded firm orders and the SkyWater acquisition adds a business with limited, cancellable backlog, so headline backlog quality is weaker than it appears. The stock's pullback from June highs makes the entry more balanced, but the price still embeds successful SkyWater integration and clean revenue conversion before those are proven. Consequently, the master report's WAIT rating remains intact pending concrete KPIs and loss discipline.

Implication

The RPO growth shows strong commercial momentum and supports management's organic revenue guidance, but investors should discount unfunded portions and note that the recent SkyWater deal introduces new backlog reliability risks. The key near-term catalyst is the September 8 investor day, where IonQ must disclose specific manufacturing yield, capacity, and delivery timing improvements to validate vertical integration. Meanwhile, adjusted EBITDA loss guidance remains at $310–$330 million for 2026, and diluted shares outstanding continue to climb, so per-share value creation still depends on converting backlog into funded, scheduled revenue. Until those proof points appear, the stock's valuation at $42.70 already prices in a clean execution path that may not materialize, leaving better risk-adjusted opportunities near $34 or after a confirmed KPI beat. Investors should monitor quarterly RPO mix between funded and unfunded orders and track SkyWater's purchase-order cancellations as early warning signs.

Thesis delta

The core thesis that IonQ needs to convert backlog into visible revenue and prove SkyWater integration is unchanged. The new RPO data is a positive incremental signal that commercial execution is tracking better than expected, but it does not resolve the quality-of-backlog or integration risks. Accordingly, the WAIT rating remains, with a slightly firmer base case if funded revenue conversion follows.